Active Ingredients: Ciprofloxacin
The patients needed to have a previous record of P.
Pneumothorax was observed in one patient. Most importantly, fewer hospitalizations were observed in the group receiving aerosolized tobramycin.
Respiratory functions were recorded, and this study presented additional data regarding forced vital capacity FVC and forced expiratory flow during the middle half of forced vital capacity FEF 25—75.
Moreover, fewer hospital admissions and fewer days of hospitalization were observed in the group receiving aerosolized tobramycin.
Further, both groups showed an increase in body weight, and no severe adverse effects were observed. Hoarseness of voice was also observed in almost all patients receiving aerosolized tobramycin. The pharmacokinetics of tobramycin were assessed in a 24-week study by Geller et al.
It has always been a point of debate whether underlying respiratory disease influences deposition of the aerosol.
However, more information is necessary regarding the site of sample collection, ie, from the central or distal airways. When the artificial tear group and the fluoroquinolone groups with corneal epithelial defect were compared, increased expression of MMPs was observed as a result of the wound healing process.
However, the fluoroquinolone treated group exhibited high statistically significantly levels of MMPs expression. Conclusions Our study provides preliminary evidence that topical application of fluoroquinolone drugs can induce the expression of MMP-1, MMP-2, MMP-8 and MMP-9 in the undebrided corneal epithelium compared to artificial tear eye drops.
Keywords: Fluoroquinolones, Levofloxacin, Ciprofloxacin, Ofloxacin, Matrix metalloproteinases, Cornea Background Since their introduction in the United States over a decade ago, the quinolone antibacterial agents have become a mainstay in the treatment of serious bacterial infections.
The fluoroquinolones are known for their extremely broad spectrum of antibacterial activity.
The structural differences of the fluorinated carboxyquinolones commercially available, for topical ophthalmic use, alter their potency as well as their pharmacological profiles.